TransCode Therapeutics, Inc.

Equities

RNAZ

US89357L3033

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-04-22 pm EDT 5-day change 1st Jan Change
0.459 USD -5.36% Intraday chart for TransCode Therapeutics, Inc. -14.41% -93.04%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Certain Warrants of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024. CI
Certain Stock Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024. CI
Certain Common Stock of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024. CI
TransCode Therapeutics Cleared by FDA for Phase 1/2 Trial of TTX-MC138 for Advanced Solid Tumors MT
TransCode Therapeutics, Inc. Announces Fda Clearance to Initiate Phase 1/2 Clinical Trial Withttx-Mc138 in Patients with Advanced Solid Tumors CI
TransCode Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
TransCode Therapeutics, Inc. Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer CI
TransCode Therapeutics, Inc. and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment CI
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode?s RIG-I Agonist Immunotherapeutic CI
TransCode Therapeutics, Debiopharm Collaborate to Develop Nucleic Acid Therapies for Cancer MT
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer CI
Sector Update: Health Care Stocks Softer Late Thursday Afternoon MT
Sector Update: Health Care MT
Top Midday Decliners MT
TransCode Therapeutics' Shares Tumble After Pricing Public Offering MT
Sector Update: Health Care Stocks Fall Premarket Tuesday MT
TransCode Reports Additional Restructuring Steps; Chief Executive Michael Dudley to Retire MT
TransCode Therapeutics, Inc. Announces CEO Changes CI
TransCode Therapeutics, Inc. Announces Management Changes CI
Certain Warrants of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-DEC-2023. CI
Certain Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-DEC-2023. CI
Certain Common Stock of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-DEC-2023. CI
TransCode Therapeutics, Inc. Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with Its Lead Candidate, TTX-MC138 CI
TransCode Therapeutics, Inc. to Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium CI
Certain Common Stock of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-NOV-2023. CI
Chart TransCode Therapeutics, Inc.
More charts
TransCode Therapeutics, Inc. is a ribonucleic acid (RNA) oncology company. Its lead therapeutic candidate, TTX-MC138, targets microRNA-10b (miRNA-10b), a regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and several others. Its preclinical programs include two solid tumor programs, TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 (PD-L1), and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. It also has two indication agnostic programs, TTX-RIGA, an RNA-based agonist of the retinoic acid- inducible gene I (RIG-I), targeting activation of innate immunity in the tumor microenvironment, and TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells, as well as TTX-mRNA, a tumor-type specific mRNA-based platform for the development of cancer vaccines that are designed to activate cytotoxic immune responses.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.459 USD
Average target price
3 USD
Spread / Average Target
+553.59%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. RNAZ Stock
  4. News TransCode Therapeutics, Inc.
  5. Sector Update: Health Care Stocks Softer Late Thursday Afternoon